Round Type
Series A
San FranciscoBiotechnologyDescription
GenEdit, Inc., a biotechnology company with a mission to develop curative therapies through targeted in vivo delivery of genetic medicines, today announced that it has closed a $26 million Series A financing. New investors Eli Lilly, KTB Network, Ltd., Company K Partners, Korea Investment Partners, DAYLI Partners, KB Investment, IMM Investment, and TIMEFOLIO Asset Management, join existing investors DCVC Bio, SK Holdings, Bow Capital, and Sequoia Capital, participating in the financing. The funding will support the further development of GenEdit’s NanoGalaxyTM platform of non-viral, non-lipid polymer nanoparticles, and the selection for clinical development of therapeutic candidates targeting diseases of the nervous system.
Quick answer
GenEdit raised an undisclosed amount in a Series A round, dated September 23, 2021. GenEdit is based in San Francisco, California, United States.
- How much did GenEdit raise?
- GenEdit raised an undisclosed amount in a Series A round on September 23, 2021.
- What does GenEdit do?
- GenEdit is focused on overcoming the major challenge to genetic medicines: Delivery.
- Where is GenEdit based and how big is it?
- GenEdit is based in San Francisco, California, United States.
- Who are the decision-makers at GenEdit?
- Fundz holds 1 contact at GenEdit. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Biotechnology around the same time
Companies in the same sectors as GenEdit that raised within 45 days of this round, from Fundz verified event records.
- Pison Technology, Inc. raised $1.4M (Seed) on November 5, 2021.
- CuraSen Therapeutics raised $18M on November 5, 2021.
- NERx Biosciences, Inc. raised $200K (Seed) on November 5, 2021.
- GlycoEra AG raised an undisclosed amount (Series A) on November 5, 2021.
- Sway raised $2.5M (Seed) on November 4, 2021.
- National Comprehensive Cancer Network raised an undisclosed amount (Funding Round) on November 4, 2021.
Who to call at GenEdit, and when
A new round usually means GenEdit is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day GenEdit raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at GenEdit, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at GenEdit. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment GenEdit raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansGenEdit raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.